Alnylam Pharmaceuticals, Inc. (ALNY) Earnings — Revenue, EPS & EBITDA | Market Terminal

Market Terminal

Get Full Access To
Market Terminal For Free

Real-time breakouts. AI-powered analysis. The terminal that levels the playing field.

Open Terminal

BreakoutsScreenerAI AnalysisCalendarsMarketsNewsletters

Market Terminal

Get Full Access To
Market Terminal For Free

Real-time breakouts. AI-powered analysis. The terminal that levels the playing field.

Open Terminal

BreakoutsScreenerAI AnalysisCalendarsMarketsNewsletters

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1).

Get Full Access To Market Terminal For Free

Get Full Access To Market Terminal For Free

Alnylam Pharmaceuticals, Inc. (ALNY)

Explore More Tools

Get Full Access To
Market Terminal For Free

Get Full Access To
Market Terminal For Free